Nose-to-Brain Targeted Delivery of Donepezil Hydrochloride via Novel Hyaluronic Acid-Doped Nanotransfersomes for Alzheimer's Disease Mitigation

Salem, Heba F.; Aboud, Heba M.; Abdellatif, Mostafa M.; Abou-Taleb, Heba A.

doi:10.1016/j.xphs.2024.02.014

Cited by 2 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemolytic toxicity studies of pure EGCG and AA, EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS were done with slight modifications from the reported protocol. 17 From a healthy subject, 8 mL of whole blood was collected and stored in an EDTA-coated vial. The blood samples were suspended in a normal saline solution (0.9% w/v).…”

Section: In Vitro Release Study For Drugmentioning

confidence: 99%

“…These nanotransferosomes were nontoxic, tolerable, and had a high nose-to-brain transport percentage (80.32%). 17 Gupta et al reported naringin-loaded transniosomes for the treatment of epilepsy. The developed transniosomes had permeation across the nasal mucosa, and intranasally administered transniosomes had a greater C max and AUC 0−24 h than orally administered transniosomes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies

Mishra,

Awasthi,

Mishra

et al. 2024

ACS Omega

View full text Add to dashboard Cite

and ascorbic acid (AA)-loaded transferosomes (TRANS) were developed for brain delivery. The investigation covered EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS formulations using the film hydration technique. We analyzed the formed transferosomes to confirm the presence of vesicles loaded with the respective drugs and their performance within a living organism. The sizes of the particles for EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS were measured correspondingly at 174.2 ± 1.80, 132.7 ± 12.22, and 184.31 ± 9.5 nm. The appearance of diffused rings in the scanning electron microscopic image suggests that the payload has a crystalline structure. The atomic force microscope image displayed minimal surface irregularities, potentially indicating the presence of a lipid layer on the surface. Hemolysis results indicated the safety of the vesicles. The results showed 10.23, 7.21, and 8.20% of hemolysis for EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS, respectively. In the case of EGCG-AA-TRANS, the release of EGCG was determined to be 61.65% ± 4.61 after 72 h when exposed to phosphate buffer saline (pH 7.4). In vivo studies show a good response against Alzheimer's disease (AD). EGCG-AA-TRANS (82.166%) exhibited a higher percentage of AChE inhibition in comparison to EGCG-TRANS (66.550%) and AA-TRANS (53.466%). Intranasal delivery of EGCG-AA-TRANS resulted in approximately a 5-fold enhancement in memory. Formulation allowed EGCG and AA to accumulate in various organs, including the brain. The results suggest that EGCG-AA-TRANS could be safe and effective for treating AD.

show abstract

Section: In Vitro Release Study For Drugmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%